| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/04/2014 | US8642049 Vaccine against group A beta hemolytic streptococcus and respective process for obtaining thereof |
| 02/04/2014 | US8642048 Multiple antigenic peptides immunogenic against Streptococcus pneumonia |
| 02/04/2014 | US8642047 Non-protein stabilized Clostridial toxin pharmaceutical compositions |
| 02/04/2014 | US8642046 Cholera vaccines |
| 02/04/2014 | US8642044 Prevention and treatment of amyloidogenic disease |
| 02/04/2014 | US8642043 Peptide epitopes of apolipoprotein B |
| 02/04/2014 | US8642042 Protein matrix vaccines and methods of making and administering such vaccines |
| 02/04/2014 | US8642041 Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation |
| 02/04/2014 | US8642040 Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists |
| 02/04/2014 | US8642039 Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection |
| 02/04/2014 | US8642038 Isolated egg protein and egg lipid materials, and methods for producing the same |
| 02/04/2014 | US8642037 Antibodies to insulin-like growth factor I receptor |
| 02/04/2014 | US8642036 Treatment with anti-ErbB2 antibodies |
| 02/04/2014 | US8642035 Anti-TrkB antibodies |
| 02/04/2014 | US8642034 Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
| 02/04/2014 | US8642033 Methods for inducing in vivo tolerance |
| 02/04/2014 | US8642032 Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient |
| 02/04/2014 | US8642031 Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| 02/04/2014 | US8642011 Tuberculosis vaccine |
| 02/04/2014 | CA2782650C Arranging interaction and back pressure chambers for microfluidization |
| 02/04/2014 | CA2780425C Hydrophilic filtration during manufacture of vaccine adjuvants |
| 02/04/2014 | CA2606890C Immunogens for meningitidis-a vaccines |
| 02/04/2014 | CA2595024C Methods for the production of ansamitocins |
| 02/04/2014 | CA2548180C Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| 02/04/2014 | CA2543484C Modulation of immune response to an immunogen with ctla-4 and tnfbp |
| 02/04/2014 | CA2539273C A fusion protein comprising an interleukin-1 receptor antagonist and uses thereof |
| 02/04/2014 | CA2507055C Treatment of prion-induced diseases by administration of anti-prion antibodies |
| 02/04/2014 | CA2498008C Novel composition and methods for the treatment of immune related diseases |
| 02/04/2014 | CA2453470C Use of follistatin for the treatment of hepatic fibrogenesis |
| 02/04/2014 | CA2326388C A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
| 02/04/2014 | CA2301879C Tuberculosis vaccine |
| 01/30/2014 | WO2014018931A1 Methods and compositions for treating autoimmune disease |
| 01/30/2014 | WO2014018904A1 Fused antigen vaccines and compositions against streptococcus pneumoniae |
| 01/30/2014 | WO2014018858A2 Multimeric fusion protein vaccine and immunotherapeutic |
| 01/30/2014 | WO2014018850A2 Cytoplasmic tail modifications to boost surface expression and immunogenicity of envelope glycoproteins |
| 01/30/2014 | WO2014018841A1 Methods of treating fgfr3 related conditions |
| 01/30/2014 | WO2014018801A1 Diagnosis and treatment of cancer using differentially expressed starvation markers |
| 01/30/2014 | WO2014018724A1 Tick toxin compositions |
| 01/30/2014 | WO2014018673A2 Fusion proteins and methods thereof |
| 01/30/2014 | WO2014018625A1 Anti-kit antibodies and uses thereof |
| 01/30/2014 | WO2014018620A1 Methods and compounds for reducing threonyl-trna synthetase activity |
| 01/30/2014 | WO2014018554A1 Ptprs and proteoglycans in autoimmune disease |
| 01/30/2014 | WO2014018535A1 Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| 01/30/2014 | WO2014018274A1 Compositions comprising chimeric ospa molecules and methods of use thereof |
| 01/30/2014 | WO2014018117A1 An mva vaccine for delivery of a ul128 complex and preventing cmv infection |
| 01/30/2014 | WO2014018113A1 Oncolytic virus therapy for resistant tumors |
| 01/30/2014 | WO2014018018A1 Composition and method for reducing tissue damage from inflammatory disorder or pathogenic infection |
| 01/30/2014 | WO2014017493A1 Vaccine |
| 01/30/2014 | WO2014017462A1 Pharmaceutical composition for inhibiting abnormal spine formation |
| 01/30/2014 | WO2014016737A1 Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| 01/30/2014 | WO2014016383A2 Glycoproteins for pseudotyping lentivectors |
| 01/30/2014 | WO2014016362A1 Vaccine compositions for prevention against dengue virus infection |
| 01/30/2014 | WO2014016360A1 Vaccine compositions |
| 01/30/2014 | WO2014016312A1 Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders |
| 01/30/2014 | WO2014016152A1 Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| 01/30/2014 | WO2014015816A1 Method for removing host dna from vaccine |
| 01/30/2014 | WO2014015804A1 Method for preparing homodimer protein mixture by using charge repulsion effect |
| 01/30/2014 | WO2013184938A3 Fusion polypeptides comprising mucin-domain polypeptide linkers |
| 01/30/2014 | WO2013155526A3 Sortase- modified vhh domains and uses thereof |
| 01/30/2014 | WO2013128418A3 Peptide inhibitors as novel anti-hiv therapeutics |
| 01/30/2014 | US20140033335 Immunoglobulin 2 |
| 01/30/2014 | US20140030342 Process for producing an immunogenic composition containing tetanus toxoid |
| 01/30/2014 | US20140030296 Vaccine adjuvant |
| 01/30/2014 | US20140030295 Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response |
| 01/30/2014 | US20140030290 Infectious Clones of RNA Viruses and Vaccines and Diagnostic Assays Derived Thereof |
| 01/30/2014 | US20140030285 Altered OSPA of Borrelia Burgdorferi |
| 01/30/2014 | US20140030276 Cancer immunopotentiating agent containing rankl antagonist |
| 01/30/2014 | US20140030275 A-beta binding polypeptides |
| 01/30/2014 | US20140030273 Human antibodies and antibody-drug conjugates against cd74 |
| 01/30/2014 | US20140030268 Treatment for bone diseases |
| 01/30/2014 | US20140030266 Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated With D-DT |
| 01/30/2014 | US20140030263 Treatment of diffuse large-cell lymphoma with anti-cd20 antibody |
| 01/30/2014 | US20140030262 Materials and methods for evaluating and treating neuromyelitis optica (nmo) |
| 01/30/2014 | US20140030259 Methods of treating fgfr3 related conditions |
| 01/30/2014 | US20140030257 Agtr1 as a marker for bevacizumab combination therapies |
| 01/30/2014 | US20140030256 Benzoxazole kinase inhibitors and methods of use |
| 01/30/2014 | US20140030253 HUMANIZED FORMS OF MONOCLONAL ANTIBODIES TO HUMAN GnRH RECEPTOR |
| 01/30/2014 | US20140030251 Composition and method for reducing tissue damage from inflammatory disorder or pathogenic infection |
| 01/30/2014 | US20140030220 Recombinant fusion interferon for animals |
| 01/30/2014 | US20140030217 Vaccine immunotherapy |
| 01/30/2014 | US20140030216 Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors |
| 01/30/2014 | US20140030212 Compositions, methods and devices for activating an immune response |
| 01/30/2014 | CA2875391A1 Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| 01/29/2014 | EP2690438A1 Synthesis of diverse glycosylphosphatidylinositol glycans and glycolipids from toxoplasma gondii and their application as diagnostic markers and vaccines |
| 01/29/2014 | EP2690111A1 Anti-mouse aggrus monoclonal antibody |
| 01/29/2014 | EP2689787A1 Identification and enrichment of cell subpopulations |
| 01/29/2014 | EP2689786A1 HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders |
| 01/29/2014 | EP2689785A1 Method for generating dry vaccine powder formulation for intranasal delivery |
| 01/29/2014 | EP2689775A1 Cochleate with only one mamp |
| 01/29/2014 | EP2689016A1 Immunogenic compositions in particulate form and methods for producing the same |
| 01/29/2014 | EP2688910A1 Anti - sclerostin antibody crystals and formulations thereof |
| 01/29/2014 | EP2688908A1 Targeted cytokine for treatment of musculoskeletal diseases |
| 01/29/2014 | EP2688904A1 Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy |
| 01/29/2014 | EP2688867A1 Heterobifunctional esters for use in labeling target molecules |
| 01/29/2014 | EP2688592A1 Compositions and methods to immunize against hepatitis c virus |
| 01/29/2014 | EP2688591A1 Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine |
| 01/29/2014 | EP2688590A1 Adjuvant nanoemulsions with phospholipids |
| 01/29/2014 | EP2688589A1 Method for the production of protein complexes and vaccine compositions comprising the same |
| 01/29/2014 | EP2688588A1 Rapid and prolonged immunologic-therapeutic |
| 01/29/2014 | EP2688587A1 Salmonid alphavirus vaccine |